Claims for Patent: 8,088,771

Summary for Patent: 8,088,771

Title:	Cycloalkylidene and heterocycloalkylidene inhibitor compounds
Abstract:	The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. ##STR00001##
Inventor(s):	Melvin, Jr.; Lawrence S. (Longmont, CO), Graupe; Michael (Pacifica, CA), Venkataramani; Chandrasekar (Redwood City, CA), Guerrero; Juan A. (Concord, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	12/510,809
Patent Claims:	1. A compound selected from those of Formula (I) or a pharmaceutically acceptable salts thereof: ##STR00426## wherein Cy.sup.1 is heterocycloalkylidene; Cy.sup.2 is thiazol-2-yl; Ar is phenyl; m is an integer from 0 to the maximum number of substitutable positions on Ar; n is an integer from 0 to the maximum number of substitutable positions on Cy.sup.1; p is an integer equal to the number of substitutable positions on Cy.sup.2; R.sup.1 is hydroxyl, aryl or heteroaryl, wherein aryl or heteroaryl is substituted with --NH.sub.2 or --OH, and aryl or heteroaryl is optionally further substituted with one or more groups selected from amino, halo, cyano, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, haloaryl and haloheterocyclyl, wherein alkyl, alkenyl or alkynyl is optionally further substituted with one or more groups selected from halo, hydroxyl, alkyl, haloalkyl, cycloalkyl, halophenyl, heterocyclyl, and trialkylsilyl; R.sup.2 is independently selected from the group consisting of halo, hydroxyl, oxo, nitro, cyano, trifluoromethyl, trifluoromethoxy, amino, carboxyl, carbamoyl, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, C.sub.1-10 alkanoyl, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2 amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2 carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, NH.sub.2--S(O).sub.2NH--, N--(C.sub.1-10 alkyl)sulphamoyl, N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, cycloalkyl, heterocyclyl and aryl; R.sup.3 is independently selected from the group consisting of halo, hydroxyl, oxo, nitro, cyano, trifluoromethyl, trifluoromethoxy, amino, carboxyl, carbamoyl, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, C.sub.1-10 alkanoyl, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2 amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2 carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, NH.sub.2--S(O).sub.2NH--, N--(C.sub.1-10 alkyl)sulphamoyl, N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, cycloalkyl, heterocyclyl and aryl, wherein each R.sup.3 is optionally substituted by one or more A; or two groups R.sup.3 are substituted on the same carbon ring atom of Cy.sup.1 and together with the carbon ring atom of Cy.sup.1 form a ring situated on Cy.sup.1 in a spiro configuration, wherein the spiro ring is cycloalkyl or heterocycloalkyl; R.sup.4 is independently selected from the group consisting of H, halo, nitro, cyano, hydroxyl, oxo, hydroxy(C.sub.1-10 alkyl), amino(C.sub.1-10 alkyl), haloalkyl, haloalkoxy, amino, azido, carboxyl, carbamoyl, mercapto, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, hydroxy(C.sub.1-10 alkoxy)(C.sub.1-10 alkoxy), (C.sub.1-10 alkoxy)(C.sub.1-10 alkoxy), (C.sub.1-10 alkoxy)(C.sub.1-10 alkyl), C.sub.1-10 alkanoyl, C.sub.1-10 alkanoyloxy, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, C.sub.1-10 alkoxycarbonyl, NH.sub.2--S(O).sub.2NH--, NH.sub.2--CO--NH--, N--(C.sub.1-10 alkyl)sulphamoyl, N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, aryl, arylalkyl, aryloxy, arylthio, cycloalkyl, cycloalkylalkyl, cycloalkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyl(C.dbd.O)--, heterocyclyloxy and heterocyclylthio, wherein if R.sup.4 is not aryl, cycloalkyl or heterocyclyl, each R.sup.4 is optionally substituted by one or more B, and if R.sup.4 is aryl, cycloalkyl or heterocyclyl, R.sup.4 is optionally further substituted by one or more R.sup.5, or when p is 2 or greater, two R.sup.4 groups form a 5- or 6-membered cyclic moiety to make a fused ring with Cy.sup.2 ring, wherein the cyclic moiety can contain one or more heteroatoms selected from N, O and S and the fused ring is optionally substituted by one or more R.sup.5; R.sup.5 is independently selected from halo, nitro, cyano, hydroxyl, oxo, hydroxy(C.sub.1-10 alkyl), amino(C.sub.1-10 alkyl), haloalkyl, haloalkoxy, amino, azido, carboxyl, carbamoyl, mercapto, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, hydroxy(C.sub.1-10 alkoxy)(C.sub.1-10 alkoxy), (C.sub.1-10 alkoxy)(C.sub.1-10 alkoxy), (C.sub.1-10 alkoxy)(C.sub.1-10 alkyl), C.sub.1-10 alkanoyl, C.sub.1-10 alkanoyloxy, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2carbamoyl, C.sub.1-10 alkyl-S(O), wherein a is 0, 1 or 2, C.sub.1-10 alkoxycarbonyl, NH.sub.2--S(O).sub.2NH--, NH.sub.2--CO--NH--, N--(C.sub.1-10 alkyl)sulphamoyl, N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, aryl, arylalkyl, aryloxy, arylthio, cycloalkyl, cycloalkylalkyl, cycloalkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyl(C.dbd.O)--, heterocyclyloxy and heterocyclylthio, wherein each R.sup.5 is optionally substituted by one or more D; and A, B and D are independently selected from halo, nitro, cyano, hydroxyl, oxo, hydroxyalkyl, haloalkyl, haloalkoxy, amino, azido, carboxyl, carbamoyl, mercapto, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, C.sub.1-10 alkanoyl, C.sub.1-10 alkanoyloxy, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, C.sub.1-10 alkoxycarbonyl, N--(C.sub.1-10 alkyl)sulphamoyl, N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, H.sub.2NS(O).sub.2NH--, N--(C.sub.1-10 alkyl)NHS(O).sub.2NH--, N,N--(C.sub.1-10 alkyl).sub.2NS(O).sub.2NH--, aryl, aryloxy, arylthio, cycloalkyl, cycloalkyloxy, heterocyclyl, heterocyclyl(C.dbd.O)--, heterocyclyloxy and heterocyclylthio. 2. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R.sup.1 is hydroxyl, phenyl or 5-membered or 6-membered heteroaryl, wherein phenyl or heteroaryl is substituted with --NH.sub.2 or --OH at a ring position adjacent to attachment of the --CONH-moiety, and phenyl or heteroaryl is optionally further substituted with one or more substituent selected from amino, halo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, haloaryl, and haloheterocyclyl, wherein alkyl, alkenyl, or alkynyl is optionally further substituted with one or more groups selected from halo, hydroxyl, alkyl, haloalkyl and cycloalkyl. 3. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy.sup.1 is C.sub.3-7 heterocycloalkylidene having from 3 to 7 ring members. 4. The compound or pharmaceutically acceptable salt thereof of claim 1 having the structure of Formula (I-a): ##STR00427## wherein m is 0, 1, 2, 3 or 4; Cy.sup.1 is C.sub.3-7 heterocycloalkylidene; R.sup.1 is hydroxyl, aryl or heteroaryl, wherein aryl or heteroaryl is substituted with --NH.sub.2 or --OH at a ring position adjacent to attachment of the --CONH-moiety, and aryl or heteroaryl is optionally further substituted with one or more substituent selected from amino, halo, cyano, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, haloaryl, and haloheterocyclyl, wherein alkyl, alkenyl, or alkynyl is optionally further substituted with one or more groups selected from halo, hydroxyl, alkyl, haloalkyl, cycloalkyl, halophenyl, heterocyclyl, and trialkylsilyl; and each R.sup.4 is independently selected from H, halo, nitro, cyano, hydroxyl, hydroxy(C.sub.1-10 alkyl), haloalkyl, haloalkoxy, amino, azido, carboxyl, carbamoyl, mercapto, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, C.sub.1-10 alkanoyl, C.sub.1-10 alkanoyloxy, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, C.sub.1-10 alkoxycarbonyl, NH.sub.2--S(O).sub.2NH--, N--(C.sub.1-10 alkyl)sulphamoyl, N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, aryl, cycloalkyl and heterocyclyl wherein if R.sup.4 is not aryl, cycloalkyl or heterocyclyl, each R.sup.4 is optionally substituted by one or more B, and if R.sup.4 is aryl, cycloalkyl or heterocyclyl, R.sup.4 is optionally further substituted by one or more R.sup.5, or when the compound is selected from Formula (I-a) and (I-b), p is 2 and two R.sup.4 groups are substituted at positions 4 and 5 of the thiazole ring and form a 5- or 6-membered cyclic moiety to make a fused ring with the thiazole ring, wherein the cyclic moiety can contain one or more heteroatoms selected from N, O and S and the fused ring is optionally substituted by one or more R.sup.5. 5. The compound or pharmaceutically acceptable salt thereof of claim 4 which has a formula selected from the group consisting of: ##STR00428## ##STR00429## ##STR00430## wherein q is 2, 3, 4, or 5; Q is a ring atom independently selected from C, N, O, and S, wherein at least one Q is a hetero ring atom selected from N, O and S; R.sup.6 and R.sup.7 are independently selected from H, halo, nitro, cyano, hydroxyl, hydroxyalkyl, haloalkyl, haloalkoxy, amino, azido, carboxyl, carbamoyl, mercapto, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, C.sub.1-10 alkanoyl, C.sub.1-10 alkanoyloxy, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, C.sub.1-10 alkoxycarbonyl, NH.sub.2--S(O).sub.2NH--, N--(C.sub.1-10 alkyl)sulphamoyl and N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, or form a 5- or 6-membered cyclic moiety to make a fused ring with the thiazole ring, wherein the cyclic moiety can contain one or more heteroatoms selected from N, O and S; wherein each R.sup.6 and R.sup.7 is optionally substituted by one or more B; and R.sup.6', R.sup.7', R.sup.8, R.sup.9 and R.sup.10 are independently selected from H and the functional groups of R.sup.5; wherein each R.sup.6', R.sup.7', R.sup.8, R.sup.9 and R.sup.10 is optionally substituted by one or more D. 6. The compound or pharmaceutically acceptable salt thereof of claim 5 which is selected from those of Structures (A''0) and (A''10): ##STR00431## 7. The compound of claim 5 which is selected from the group consisting of: N-hydroxy-4-(4-(4-(imidazo[1,2-a]pyridin-3-yl)thiazol-2-yl)tetrahydro- pyran-4-yl)benzamide; N-hydroxy-4-(4-(4-(imidazo[1,2-a]pyridin-3-yl)-5-methylthiazol-2-yl)tetra- hydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(imidazo[1,2-a]pyridin-3-yl)thiazol-2-yl)tetrah- ydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(imidazo[1,2-a]pyridin-3-yl)-5-methylthiazol-2-- yl)tetrahydropyran-4-yl)benzamide; N-hydroxy-4-(4-(4-(2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2-yl)tetrah- ydropyran-4-yl)benzamide; N-hydroxy-4-(4-(5-methyl-4-(2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2-- yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2-y- l)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(5-methyl-4-(2-methylimidazo[1,2-a]pyridin-3-yl)th- iazol-2-yl)tetrahydropyran-4-yl)benzamide; 4-(4-(4-(6-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2-yl)tetrahy- dropyran-4-yl)-N-hydroxybenzamide; N-(2-aminophenyl)-4-(4-(4-(6-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)th- iazol-2-yl)tetrahydropyran-4-yl)benzamide; N-hydroxy-4-(4-(4-(7-methoxy-2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2- -yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(7-methoxy-2-methylimidazo[1,2-a]pyridin-3-yl)t- hiazol-2-yl)tetrahydropyran-4-yl)benzamide; 4-(4-(4-(7-((dimethylamino)methyl)imidazo[1,2-a]pyridin-3-yl)thiazol-2-yl- )tetrahydropyran-4-yl)-N-hydroxybenzamide; N-(2-aminophenyl)-4-(4-(4-(7-((dimethylamino)methyl)imidazo[1,2-a]pyridin- -3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-hydroxy-4-(4-(4-(7-(pyrrolidin-1-ylmethyl)imidazo[1,2-a]pyridin-3-yl)th- iazol-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(7-(pyrrolidin-1-ylmethyl)imidazo[1,2-a]pyridin- -3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-hydroxy-4-(4-(4-(7-(morpholinomethyl)imidazo[1,2-a]pyridin-3-yl)thiazol- -2-yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(7-(morpholinomethyl)imidazo[1,2-a]pyridin-3-yl- )thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-hydroxy-4-(4-(4-(2-methyl-6-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl- )thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(2-methyl-6-(trifluoromethyl)imidazo[1,2-a]pyri- din-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-hydroxy-4-(4-(4-(2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl- )thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyri- din-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; 3-(2-(4-(4-(hydroxycarbamoyl)phenyl)tetrahydropyran-4-yl)thiazol-4-yl)-N-- (2-methoxyethyl)-2-methylimidazo[1,2-a]pyridine-7-carboxamide; 3-(2-(4-(4-(2-aminophenylcarbamoyl)phenyl)tetrahydropyran-4-yl)thiazol-4-- yl)-N-(2-methoxyethyl)-2-methyl imidazo[1,2-a]pyridine-7-carboxamide; 4-(4-(4-(7-cyano-2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2-yl)tetrahyd- ropyran-4-yl)-N-hydroxybenzamide; N-(2-aminophenyl)-4-(4-(4-(7-cyano-2-methylimidazo[1,2-a]pyridin-3-yl)thi- azol-2-yl)tetrahydropyran-4-yl)benzamide; 3-(2-(4-(4-(hydroxycarbamoyl)phenyl)tetrahydropyran-4-yl)thiazol-4-yl)-2-- methyl-N-(2-morpholinoethyl)imidazo[1,2-a]pyridine-7-carboxamide; 3-(2-(4-(4-(2-aminophenylcarbamoyl)phenyl)tetrahydropyran-4-yl)thiazol-4-- yl)-2-methyl-N-(2-morpholinoethyl)imidazo[1,2-a]pyridine-7-carboxamide; methyl 3-(2-(4-(4-(hydroxycarbamoyl)phenyl)tetrahydropyran-4-yl)thiazol-4- -yl)-2-methylimidazo[1,2-a]pyridine-7-carboxylate; methyl 3-(2-(4-(4-(2-aminophenylcarbamoyl)phenyl)tetrahydropyran-4-yl)thiazol-4-- yl)-2-methyl imidazo[1,2-a]pyridine-7-carboxylate; N-hydroxy-4-(4-(4-(2-methyl-7-(4-methylpiperazine-1-carbonyl)imidazo[1,2-- a]pyridin-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(2-methyl-7-(4-methylpiperazine-1-carbonyl)imid- azo[1,2-a]pyridin-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; 3-(2-(4-(4-(hydroxycarbamoyl)phenyl)tetrahydropyran-4-yl)thiazol-4-yl)-2-- methylimidazo[1,2-a]pyridine-7-carboxylic acid; 3-(2-(4-(4-(2-aminophenylcarbamoyl)phenyl)tetrahydropyran-4-yl)thiazol-4-- yl)-2-methylimidazo[1,2-a]pyridine-7-carboxylic acid; N-hydroxy-4-(4-(4-(2-methyl-7-(2-morpholinoethoxy)imidazo[1,2-a]pyridin-3- -yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(2-methyl-7-(2-morpholinoethoxy)imidazo[1,2-a]p- yridin-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; 4-(4-(4-(7-(2-(dimethylamino)ethoxy)-2-methylimidazo[1,2-a]pyridin-3-yl)t- hiazol-2-yl)tetrahydropyran-4-yl)-N-hydroxybenzamide; N-(2-aminophenyl)-4-(4-(4-(7-(2-(dimethylamino)ethoxy)-2-methylimidazo[1,- 2-a]pyridin-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-hydroxy-4-(4-(4-(7-(2-methoxyethoxy)-2-methylimidazo[1,2-a]pyridin-3-yl- )thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(7-(2-methoxyethoxy)-2-methylimidazo[1,2-a]pyri- din-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; 4-(4-(4-(7-(2-(dimethylamino)ethylamino)-2-methylimidazo[1,2-a]pyridin-3-- yl)thiazol-2-yl)tetrahydropyran-4-yl)-N-hydroxybenzamide; N-(2-aminophenyl)-4-(4-(4-(7-(2-(dimethylamino)ethylamino)-2-methylimidaz- o[1,2-a]pyridin-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; 3-(2-(4-(4-(hydroxycarbamoyl)phenyl)tetrahydropyran-4-yl)thiazol-4-yl)-N-- (2-methoxyethyl)-2-methylimidazo[1,2-a]pyridine-6-carboxamide; 3-(2-(4-(4-(2-aminophenylcarbamoyl)phenyl)tetrahydropyran-4-yl)thiazol-4-- yl)-N-(2-methoxyethyl)-2-methylimidazo[1,2-a]pyridine-6-carboxamide; N-hydroxy-4-(4-(4-(2-methyl-6-(4-methylpiperazine-1-carbonyl)imidazo[1,2-- a]pyridin-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(2-methyl-6-(4-methylpiperazine-1-carbonyl)imid- azo[1,2-a]pyridin-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; 3-(2-(4-(4-(hydroxycarbamoyl)phenyl)tetrahydropyran-4-yl)thiazol-4-yl)-2-- methyl-N-(2-morpholinoethyl)imidazo[1,2-a]pyridine-6-carboxamide; 3-(2-(4-(4-(2-aminophenylcarbamoyl)phenyl)tetrahydropyran-4-yl)thiazol-4-- yl)-2-methyl-N-(2-morpholinoethyl)imidazo[1,2-a]pyridine-6-carboxamide; N-hydroxy-4-(4-(4-(6-(2-methoxyethoxy)-2-methylimidazo[1,2-a]pyridin-3-yl- )thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(6-(2-methoxyethoxy)-2-methylimidazo[1,2-a]pyri- din-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-hydroxy-4-(4-(4-(6-methoxy-2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2- -yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(6-methoxy-2-methylimidazo[1,2-a]pyridin-3-yl)t- hiazol-2-yl)tetrahydropyran-4-yl)benzamide; 4-(4-(4-(8-fluoro-2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2-yl)tetrahy- dropyran-4-yl)-N-hydroxybenzamide; N-(2-aminophenyl)-4-(4-(4-(8-fluoro-2-methylimidazo[1,2-a]pyridin-3-yl)th- iazol-2-yl)tetrahydropyran-4-yl)benzamide; 4-(4-(4-(7-((dimethylamino)methyl)-2-methyl imidazo[1,2-a]pyridin-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)-N-hydroxybe- nzamide; N-(2-aminophenyl)-4-(4-(4-(7-((dimethylamino)methyl)-2-methylimid- azo[1,2-a]pyridin-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; 4-(4-(4-(6-bromo-2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2-yl)tetrahyd- ropyran-4-yl)-N-hydroxybenzamide; N-(2-aminophenyl)-4-(4-(4-(6-bromo-2-methylimidazo[1,2-a]pyridin-3-yl)thi- azol-2-yl)tetrahydropyran-4-yl)benzamide; N-hydroxy-4-(4-(4-(7-methoxy-2-(trifluoromethyl)imidazo[1,2-a]pyridin-3-y- l)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(7-methoxy-2-(trifluoromethyl)imidazo[1,2-a]pyr- idin-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-Amino-phenyl)-4-[4-(4-pyridin-3-yl-thiazol-2-yl)-tetrahydro-pyran-4-- yl]-benzamide; N-(2-Amino-cyclohexa-1,5-dienyl)-4-(4-thiazol-2-yl-tetrahydro-pyran-4-yl)- -benzamide; N-(2-aminophenyl)-4-(4-(4-(6-chloropyridin-3-yl)thiazol-2-yl)tetrahydropy- ran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(6-(pyrrolidin-1-yl)pyridin-3-yl)thiazol-2-yl)t- etrahydropyran-4-yl)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(4-(5-methyl-4,5,6,7-tetrahydrothia- zolo[5,4-c]pyridin-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(4-(4-(pyridin-3-yl)thiazol-2-yl)te- trahydropyran-4-yl)benzamide; N-(2-amino-5-fluorophenyl)-4-(4-(4-(pyridin-3-yl)thiazol-2-yl)tetrahydrop- yran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(6-(2-methoxyethoxy)pyridin-3-yl)thiazol-2-yl)t- etrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)thiazol- -2-yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(6,7-dihydropyrano[4,3-d]thiazol-2-yl)tetrahydropy- ran-4-yl)benzamide; 4-(4-(5-acetyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)tetrahydropy- ran-4-yl)-N-(2-aminophenyl)benzamide; 4-(4-(5-acetyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)tetrahydropy- ran-4-yl)-N-(2-amino-5-(thiophen-2-yl)phenyl)benzamide; N-(2-aminophenyl)-4-(4-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin- -2-yl)tetrahydropyran-4-yl)benzamide; N-(2-amino-5-fluorophenyl)-4-(4-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-- c]pyridin-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(4-(4-(pyrrolidin-1-ylmethyl)thiazo- l-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(4-(4-((2-methoxyethoxy)methyl)thia- zol-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(4-(4-(morpholinomethyl)thiazol-2-y- l)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(6-(4-cyclopropylpiperazin-1-yl)pyridin-3-yl)th- iazol-2-yl)tetrahydropyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(6-(piperazin-1-yl)pyridin-3-yl)thiazol-2-yl)te- trahydropyran-4-yl)benzamide; N-(4-amino-4'-fluorobiphenyl-3-yl)-4-(4-(thiazol-2-yl)tetrahydropyran-4-y- l)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(4-(4-ethoxythiazol-2-yl)tetrahydro- pyran-4-yl)benzamide; N-(4-amino-4'-fluorobiphenyl-3-yl)-4-(4-(4-ethoxythiazol-2-yl)tetrahydrop- yran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(pyrazin-2-yl)thiazol-2-yl)tetrahydropyran-4-yl- )benzamide; N-hydroxy-4-(4-(4-(pyridin-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzami- de; N-hydroxy-4-(4-(thiazol-2-yl)tetrahydropyran-4-yl)benzamide; N-hydroxy-4-(4-(4-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)thiazol-2-yl)te- trahydropyran-4-yl)benzamide; N-(2-amino-5-(5-chlorothiophen-2-yl)phenyl)-4-(4-(thiazol-2-yl)tetrahydro- pyran-4-yl)benzamide; N-(2-amino-5-(5-methylthiophen-2-yl)phenyl)-4-(4-(thiazol-2-yl)tetrahydro- pyran-4-yl)benzamide; N-(2-aminophenyl)-4-(4-(4-(4-(4-methylpiperazin-1-yl)phenyl)thiazol-2-yl)- tetrahydropyran-4-yl)benzamide; N-(2-amino-5-(thiophen-2-yl)phenyl)-4-(4-(5-(pyridin-3-yl)thiazol-2-yl)te- trahydropyran-4-yl)benzamide; N-hydroxy-4-(4-(4-(pyrazin-2-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzami- de; N-(4-amino-4'-fluorobiphenyl-3-yl)-4-(4-(4-(pyrazin-2-yl)thiazol-2-yl)- tetrahydropyran-4-yl)benzamide; N-(2-amino-5-fluorophenyl)-4-(4-(4-(pyrazin-2-yl)thiazol-2-yl)tetrahydrop- yran-4-yl)benzamide; N-(4-amino-4'-fluorobiphenyl-3-yl)-4-(4-(5-(1-hydroxyethyl)-4-methylthiaz- ol-2-yl)tetrahydropyran-4-yl)benzamide; N-(4-amino-4'-fluorobiphenyl-3-yl)-4-(4-(4,5-dimethylthiazol-2-yl)tetrahy- dropyran-4-yl)benzamide; and N-(4-amino-4'-fluorobiphenyl-3-yl)-4-(4-(5-methylthiazol-2-yl)tetrahydrop- yran-4-yl)benzamide; or a pharmaceutically acceptable salts thereof. 8. A pharmaceutical composition comprising an effective amount of one or more compounds according to claim 1 and a pharmaceutically-acceptable carrier. 9. The pharmaceutical composition according to claim 8, further comprising one or more anti-cancer agents selected from the group consisting of cyclophosphamide, dacarbazine, cisplatin, methotrexate, mercaptopurine, thioguanine, fluorouracil, cytarabine, vinblastine, paclitaxel, doxorubicin, bleomycin, mitomycin, prednisone, tamoxifen, flutamide, asparaginase, rituximab, trastuzumab, imatinib, retinoic acid, colony-stimulating factor, amifostine, lenalidomide, HDAC inhibitor, CDK inhibitor, camptothecin and topotecan.

Details for Patent 8,088,771

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2028-07-28
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-07-28
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2028-07-28
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2028-07-28
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2028-07-28
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2028-07-28